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Abstract 
Objective 
Silent myocardial infarction (MI) is a prevalent finding in patients with type 2 diabetes and is 
associated with significant mortality and morbidity. Late gadolinium enhancement (LGE) by 
cardiovascular magnetic resonance (CMR) is the most validated technique for detection of silent MI 
but is time consuming, costly and requires administration of intravenous contrast. We therefore 
planned to develop a simple and low cost population screening tool to identify those at highest risk of 
silent MI validated against the CMR reference standard.   
Methods 
100 asymptomatic patients with type 2 diabetes underwent electrocardiogram (ECG), 
echocardiography, biomarker assessment and CMR at 3.0T including assessment of left ventricular 
ejection fraction and LGE. Global longitudinal strain (GLS) from 2 and 4 chamber cines was 
measured using feature tracking.  
Results 
17/100 patients with no history of cardiovascular disease had silent MI defined by LGE in an infarct 
pattern on CMR.  Only 4 silent MI patients had Q waves on ECG. Patients with silent MI were older 
(65 vs 60, p=0.05), had lower E/A ratio (0.75 vs 0.89, p=0.004), lower GLS (-15.2% vs -17.7%, 
p=0.004) and higher NT-proBNP (106ng/L vs 52ng/L, p=0.003). A combined risk score derived from 
these 4 factors had an area under the receiver operating characteristic (ROC) curve of 0.823 (0.734-
0.892), P<0.0001. A score of ≥2/5 had 82% sensitivity and 72% specificity for silent MI. 
Conclusions 
Using measures that can be derived in an outpatient clinic setting, we have developed a novel 
screening tool for the detection of silent MI in type 2 diabetes. The screening tool had significantly 
superior diagnostic accuracy than current ECG criteria for the detection of silent MI in asymptomatic 
patients.  
  
Abbreviations 
ACR  Albumin creatinine ratio 
BSA  Body surface area 
CMR   Cardiovascular magnetic resonance 
E/A  Early and late filling velocities ratio 
ECG   Electrocardiogram 
ECV   Extracellular volume 
EDSR  Early diastolic strain rate 
FT  Feature tracking 
GLS  Global longitudinal strain 
hs-CRP  High sensitivity C reactive protein 
hs-cTnT  High sensitivity cardiac troponin T 
LDSR  Late diastolic strain rate 
LGE  Late gadolinium enhancement 
NT-proBNP Amino-terminal pro-brain natriuretic peptide  
LV  Left ventricle 
LVEF   Left ventricular ejection fraction 
ROC  Receiver operating characteristic  
MI  Myocardial infarction 
SSFP  Steady-state free precession 
SSR  Systolic strain rate 
TDI  Tissue Doppler imaging  
  
Introduction  
Cardiovascular disease, primarily stroke and myocardial infarction (MI), account for the vast majority 
of mortality associated with type 2 diabetes (1, 2). Silent MI is a relatively common finding in patients 
with type 2 diabetes (3, 4) although the exact prevalence in contemporary asymptomatic populations 
is unknown (5). 
Currently the most extensively validated method to assess for the presence and extent of silent MI is 
the late gadolinium enhancement (LGE) technique measured by cardiovascular magnetic resonance 
(CMR). Using this technique it is possible to establish the location and distribution of scar tissue. The 
prevalence of silent MI according to the presence of LGE in symptomatic patients with type 2 
diabetes is reported to be between 21-28% (3, 4). In these cohorts the presence of silent MI was 
strongly associated with an increase in major adverse cardiovascular events (MACE) and mortality.  
There has been a decrease in the rate of acute MI in patients with type 2 diabetes over the past two 
decades (6). This reduction is thought to reflect improvements in glycaemic control and modification 
of other concomitant risk factors such as smoking, dyslipidaemia and blood pressure. However, per 
definition, silent MI is usually undetected and affected patients therefore fail to benefit from 
aggressive risk factor management, which may explain the poor clinical outcome in this group.  
The detection of patients with silent MI remains a challenge as the most accurate method relies on 
CMR, which has limited availability, is relatively time consuming, costly and requires administration 
of intravenous contrast making it a less than ideal population screening tool. Several imaging and 
biomarker tests have been shown to be able to detect the presence and determine the extent of 
clinically recognised MI measured by LGE including Q waves on 12 lead electrocardiogram (ECG) 
(7), ejection fraction (8), strain parameters (9), high sensitivity troponin (hs-cTnT) (10) and amino-
terminal pro-brain natriuretic peptide (NT-proBNP) (11). However, the sensitivity and specificity of 
these tests to detect silent MI in type 2 diabetes is at present unknown.  
In this study, we aimed to assess the diagnostic accuracy of several commonly measured parameters 
in asymptomatic patients with type 2 diabetes to detect silent MI. We hypothesised that a risk score 
derived from a combination of these measurements could accurately predict the presence of silent MI 
on CMR.  
Methods 
Enrolment Criteria 
100 asymptomatic patients with type 2 diabetes were recruited from 30 primary care health centres in 
West Yorkshire, UK. The study was approved by the local ethical committee (13/YH/0098) and 
individuals were enrolled onto the study after informed consent. Exclusion criteria were known 
cardiovascular disease (including ischaemic heart disease, heart failure or persistent atrial fibrillation), 
kidney disease (eGFR <30), uncontrolled hypertension (with latest BP >140/80mmHg (12)), 
treatment with insulin or ACE inhibitor/angiotensin receptor blocker (to avoid patients with occult 
evidence of renal or other end organ damage).   
CMR protocol 
All patients underwent an identical CMR study on a dedicated cardiovascular 3 Tesla Philips Achieva 
TX system (Philips, Best, The Netherlands) equipped with a 32 channel coil and MultiTransmit® 
technology. Data were acquired during breath-holding at end expiration.  
From scout CMR images, the left ventricular long and short axes were determined. Cine images 
covering the entire heart in the LV short axis plane and orthogonal long-axis planes were then 
acquired (balanced SSFP, spatial resolution 1.2x1.2x10mm³, 50 cardiac phases TR/TE 2.6/1.3ms, flip 
angle 40o, field of view 300-420mm). Cines planned to cover the entire left atrium (LA) short axis 
plane in end systole were also acquired (as LV stack but slice thickness 5mm).  
Late gadolinium enhancement (LGE) imaging was carried out more than 6 minutes after contrast 
injection (0.15mmol/Kg Gadovist, Bayer Schering) using inversion recovery-prepared T1-weighted 
echo. The optimal inversion time to null signal from normal myocardium was determined using a 
Look-Locker approach. Typical parameters are TR/TE 3.5/2.0 ms, flip angle 25o, acquired spatial 
resolution 1.54x1.76x10mm3 and performed in 10-12 short axis slices with further slices acquired in 
the vertical and horizontal long axis orientations, phase-swapped or imaged in systole, if indicated 
based on LGE imaging obtained or wall-motion abnormality.  
CMR interpretation 
CMR data were assessed quantitatively using commercially available software (CVI42 v5.1.0, Circle 
Cardiovascular Imaging Inc. Calgary, Canada) blinded to clinical details. LV mass, ejection fraction 
(EF) and LA volume were measured from short axis cine images.  
For feature tracking analysis endocardial and epicardial LV contours were drawn on long axis 4 
chamber and 2 chamber cines using a semi-automated process. Peak global longitudinal strain, 
systolic strain rate, early and late diastolic strain rates were measured. Late diastolic strain rates were 
defined as peak rate during active atrial contraction.  
The presence of silent MI was identified by 2 physicians experienced (5 and 15 years) in CMR 
interpretation based upon typical subendocardial distribution of LGE present. The mass of LGE was 
quantified by the Otsu method (13).  
Echocardiography, Electrocardiography and 24 hour Blood Pressure monitoring 
All patients underwent echocardiography (Vivid e9, GE Medical Systems, Milwaukee, WI, USA) 
focused on Doppler measurements of mitral inflow and tissue Doppler imaging (TDI) of the lateral 
and medial mitral annulus. E/A ratio (the inverse was used for the index), E', A' and S' are measured 
on the machine using inbuilt software. Diastolic dysfunction was graded 0-3 by an accredited 
echocardiographer blinded to clinical details according to international guidelines (14). 12 lead 
electrocardiography (MAC500, GE Medical Systems, Milwaukee, WI, USA) was analysed by 2 
physicians blinded to clinical details for the presence of Q waves according to international guidelines 
(15).  All patients underwent 24 hour blood pressure monitoring (6100, Welch-Allyn, Skaneateles 
Falls, NY, USA) set to inflate every 30 minutes in the day and every hour at night.  
Blood tests 
Blood was drawn from each subject at the time of CMR and tested for HbA1c. Serum was stored at -
70°C and tested in one batch for hs-cTnT typical coefficient of variability 4.4% at 13.7ng/L and 3.6% 
at 95.3 ng/L, NT-proBNP typical coefficient of variability 2.9% at 91 ng/L and 2.1% at 415 ng/L 
(Cobas 8000, Roche Diagnostics,  Burgess Hill, West Sussex) and hs-CRP (Advia, Siemens 
Healthcare Diagnostics, Marburg, Germany). Fasting cholesterol and previous HbA1c values were 
recorded from review of electronic records.  
Statistical analysis 
Statistical analysis was performed using IBM SPSS® Statistics 22.0 (IBM Corp., Armonk, NY). 
Continuous variables were expressed as means ± standard deviation and compared using t-test or 
Mann Whitney U test depending on normality. Categorical variables were expressed as N (%) and 
compared using Fisher exact test.  
Receiver operating characteristic (ROC) analysis was used to determine the diagnostic accuracy of 
parameters that had been significantly different in those with silent MI. The diagnostic accuracy is 
expressed as area under the curve (AUC) and 95% confidence interval. Optimal sensitivity and 
specificity were calculated using Youden index. Nested models were used to establish the best 
possible AUC from combining the variables associated with silent MI. AUCs were compared by using 
validated methods described by DeLong et al (16).   
Using the cut offs derived from the Youden analysis of the ROC curves each significant variable was 
given a binary classification (0 or 1). These four categorical variables were summed to calculate a 
silent MI risk score (range 0-5). The AUC of the silent MI risk score was compared to the best 
possible AUC from the individual parameters derived from the nested risk model.  
We estimated that for a screening tool to be clinically useful it would need sensitivity >80% and to be 
significantly superior to the current screening test of Q waves which has a sensitivity of 28% (7). 
Assuming that the prevalence of silent MI in a diabetic cohort to be around 10% (4) using a 2 sided 
Fisher exact test with α=0.05 and power 80% it was calculated 98 patients would be needed, including 
10 with silent MI.  P<0.05 two-sided was considered statistically significant. 
Results 
Seventeen of the 100 patients had evidence of silent MI defined as a subendocardial pattern of LGE 
identified by two experienced CMR reporters independently. Figure 1 shows examples from 3 
patients. For the whole population mean±SD age was 60.7±10.9 years, duration of diabetes 5.0±4.4 
years, current HbA1c 63.1±19.6 mmol/mol, median HbA1c since diagnosis 64.5±17.2 mmol/mol and 
24 hour blood pressure 131.4±15.0/72.7±9.1 mmHg. Of the 100 patients 82 were male, 72 were white 
British, 19 South Asian, 6 Black, 1 Turkish, 1 Polish and 1 Latin American.  Patient characteristics 
are shown in Table 1 according to silent MI status. There was a range in the extent of silent MI from 
0.4g to 36.6g. Mean mass of infarction was 6.1±8.8g (5.8±8.5% of LV mass) and was predominantly 
subendocardial with mean transmurality of 60.3±28.0%.  
Patients with silent MI were older than those without silent MI (65.4±9.2 vs 59.8±11.0 years, P=0.05) 
but there was no significant difference in any other patient characteristic or use of medication. There 
was no significant difference in any cardiac risk factors including 24 hour BP, fasting cholesterol, 
duration of diabetes or smoking (P=0.24, 0.69, 0.24 and 0.28 respectively).  
The mean number of previous HbA1c measurements included in the analysis was 9.7±5.7 per patient 
over 4.3±2.7 years. There was no significant difference between mean, median or highest HbA1c 
since diagnosis between those with and without silent MI (P=0.69, 0.77 and 0.28 respectively).  
Electrocardiography 
Pathological Q waves on ECG were only present in 4/17 with silent MI and 6/83 without silent MI 
(sensitivity 24%, specificity 93%). Other ECG abnormalities present in 19/100 patients were not 
associated with silent MI and included left axis deviation in 5, right bundle branch block in 5, left 
ventricular hypertrophy by voltage criteria in 4, left anterior hemiblock in 3, T wave abnormalities in 
3 and trifascicular block in 1.  
Echocardiography 
Results of echocardiography are shown in Table 1. The only significant difference between those with 
and without silent MI was a lower E/A ratio (0.75±0.30 vs 0.89±0.30, P=0.03) in patients with silent 
MI. Grade of diastolic dysfunction was not significantly different between those with and without 
silent MI (grade 0, 6 vs 19%; grade 1, 88 vs 75%; grade 2, 0 vs 5%; and grade 3, 6 vs 1% P=0.24).  
Cardiovascular magnetic resonance 
CMR results are shown in Table 1. LV mass index to BSA was higher in those with silent MI than 
those without (51.4±6.5 vs 47.2±8.7g/m2, P=0.01). There was no other difference in volumetric 
parameters. Of the longitudinal strain parameters measured by feature tracking, global longitudinal 
strain (GLS) -15.2±3.7 vs -17.7±3.1%, P=0.004, peak systolic strain rate (SSR) -93.8±31.8 vs -
111.2±42%, P= 0.04 and early diastolic strain rate (EDSR) 64.1±16.6 vs 84.0±33.1%, P=0.02 were all 
significantly lower in those with silent MI. There was no difference in late diastolic strain rate 
(LDSR) P=0.89.  
Of the patient characteristics shown in Table 1 none had a significant association with quantitative 
mass of silent MI.  Of the investigation findings shown in Table 1 the mass of silent MI only had 
significant correlations with LVEF (R=-0.81, P<0.0001), E/E’ (R=-0.58, P0.02) and hs-cTnT 
(R=0.58, P=0.02).  
Biomarkers 
NT-proBNP was significantly higher in those with silent MI (105.8±132.2 vs 51.9±100.8ng/L, 
P=0.003). There was no difference in hs-CRP or hs-cTnT (P=0.57 and 0.42 respectively).   
Development of a screening tool 
The area under the ROC curve for age, Q waves, E/A ratio, GLS, and NT-proBNP are shown in Table 
2 and Appendix 1. The AUC for the nested model of all 4 variables was 0.850 (0.765-0.914), 
P<0.0001 and the maximum possible sensitivity was 94% and specificity 71%. The nested model had 
higher diagnostic accuracy than Q waves, age, E/A ratio and GLS alone (p<0.0001, 0.02, 0.02 and 
0.006 respectively). The improvement over NT-proBNP showed a trend (p=0.07). The addition of Q 
waves did not significantly improve the AUC of the model.  
The number of patients with silent MI according to their silent MI risk score is shown in Figure 2. The 
combined 4 variable silent MI risk score had an AUC of 0.823 (0.734-0.892), p<0.0001 and better 
diagnostic accuracy than Q waves, age and E/A ratio separately (p<0.0001, 0.001 and 0.02 
respectively). The sensitives and specificities for each possible silent MI risk score are shown in Table 
3.  
Discussion 
The prevalence of silent MI (17%) detected by LGE imaging in this low risk asymptomatic population 
was high approaching 1 in 5 patients. We have found increasing age to be the only conventional risk 
factor associated with silent MI. We have identified several markers of silent MI that can be detected 
by cardiac imaging or blood test and have shown that these markers can be combined to develop a 
simple screening tool with good diagnostic accuracy.  
We have demonstrated that a simple risk score can predict the presence of silent MI in patients with 
type 2 DM as shown by LGE on CMR. The risk score is composed of age, E/A ratio ≤ 0.79, GLS ≥ -
18.4% and NT-proBNP > 29ng/L. These are all parameters that are often measured in a cardiology 
clinic or could easily be measured in community based screening. In the model we derived GLS from 
feature tracking of CMR cine images. However it is possible to measure GLS from standard 
echocardiography which has been demonstrated to show good agreement with GLS measured from 
CMR (17). 
The decision about where to make the cut off to recommend further investigation depends on whether 
sensitivity or specificity is the predominant clinical priority (Table 3). If the cut off was set at a score 
≥2 (100% sensitivity and 42% specificity) it would ensure that the vast majority of silent MI was 
detected with only 2.5 patients needing CMR to identify one patient with silent MI. Alternatively if 
the cut off was higher with a score ≥3 (82% sensitivity and 72% specificity) approximately 1 in 6 
patients with silent MI would be missed but only 1.5 patients would need to be screened to detect one 
patient with silent MI. Either of these two scenarios are vastly superior to our current screening test 
using Q waves that only had 24% sensitivity in our asymptomatic cohort and 28% sensitivity in a 
cohort of patients with clinically recognised non-ST elevation MI (7).  
All of the measured components within the score namely impaired GLS (18), elevated NT-proBNP 
(19) and E/A ratio (20) have been associated with adverse outcomes in patients with type 2 diabetes 
without prior history of MI. It is likely that a proportion of the mortality reported in these patients is 
due to silent MI. It has also been shown that larger infarcts have greater impairment of GLS (9), 
higher NT-proBNP (11) and altered mitral inflow (21). Therefore all of the measured parameters have 
biological validity and prognostic significance that supports their inclusion in a risk score.  
The imaging parameters associated with mass of silent MI were different from those included in the 
silent MI risk score and included LVEF, E/E’ and hs-cTnT. These parameters are all recognised to 
correlate with extent of infarction and prognosis after symptomatic MI (8, 10, 22). However, we have 
demonstrated that they were insensitive for the detection of silent MI in type 2 diabetes and of limited 
value in this setting.  
It was an unexpected finding that conventional risk factors including fasting cholesterol, 24 hour BP, 
smoking and even previous glycaemic control had no association with the likelihood of silent MI in 
our population, although this may reflect a relatively small sample size and appropriate use of primary 
prevention medication. However, it is unclear whether the pathological processes that lead to silent 
MI are identical to acute MI. The lack of association with conventional risk factors suggests that 
further research is needed to identify alternative risk factors specifically for silent MI.  
To our knowledge this is the first study to assess silent MI by LGE CMR in a truly asymptomatic 
diabetic population. Previous studies have demonstrated that in patients with diabetes, silent MI 
detected on CMR is associated with increased mortality and adverse cardiovascular events (3, 4). 
Kwong et al reported an incidence of silent MI of 28% in symptomatic patients with diabetes 
undergoing clinical CMR (3). Schelbert et al reported a prevalence of 21% of silent MI of diabetic 
patients enrolled in the ICELAND MI study who underwent CMR between 2004 and 2007 (4). 
However patients in both studies were not necessarily asymptomatic and in ICELAND MI 28% of 
those with silent MI had prior coronary revascularisation. The rate of infarction was similar between 
our study and the work of Schelbert et al despite patients in our study being younger, lower risk and 
asymptomatic.  
Despite recommendations of aggressive risk factor modification in type 2 diabetes uptake remains 
variable (23) (with only 18% taking aspirin at time of recruitment to this study). Recognition of silent 
MI in these patients should prompt aggressive risk factor modification, which may improve long-term 
clinical outcome. Furthermore, the silent MI screening components that we have identified may help 
in future clinical studies by identifying those most likely to have silent MI who could be targeted with 
lifestyle, pharmacological or interventional management.  
Limitations 
There a number of limitations to this work that should be acknowledged. First, we have excluded 
certain higher risk patients, for example those on insulin or ACE inhibitors and therefore general 
applicability of the findings is uncertain. The silent MI risk model we propose would need to be 
validated in more varied populations to broaden its clinical use. Second, we have not performed 
coronary angiography to confirm that silent MI was caused by coronary disease. However in an 
asymptomatic cohort undertaking an invasive procedure would not be appropriate. Third, we have 
recruited a relatively low proportion of women. However previous data suggest that the rate of silent 
MI tends to be equal or lower in women (3, 4). Finally, the cut off points that we have used are based 
on Youden index which assigns equal importance to sensitivity and specificity. Depending on which 
of these is more important in clinical practice the thresholds would need to be altered accordingly. We 
have also assigned an equal score to each of the components which may oversimplify the complex 
nature of the disease process.  
Conclusions 
The rate of silent MI in this low risk asymptomatic cohort of patients with type 2 diabetes was higher 
than expected. No conventional risk factors other than age were associated with silent MI. Several 
simple clinical parameters including ECG Q waves, E/A ratio, GLS and NT-proBNP were associated 
with silent MI. By combining them we were able to define a novel screening tool with good 
diagnostic accuracy for the detection of silent MI which can be used both clinically and for 
interventional studies.  
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Silent MI 
No Silent 
MI 
P value  
N 17 83  
Age 65.4±9.2 59.8±11.0 0.05 
Male gender, n (%) 16 (94) 66 (80) 0.30 
Body mass index , kg/m
2
 27.8±3.1 28.9±4.6 0.32 
Duration of diabetes, years 4.1±4.1 5.2±4.4 0.24 
Current HbA1c, mmol/mol 57.1±12.5 64.3±20.6 0.23 
Median HbA1c since diagnosis, 
mmol/mol 
63.3±10.9 64.8±18.2 0.77 
24 hr systolic BP, mmHg 135.3±15.9 130.8±14.7 0.24 
24 hr diastolic BP, mmHg 72.5±10.1 72.7±8.9 0.89 
Total cholesterol 4.3±1.2 4.4±1.1 0.69 
Smoking, n (%) 4 (24) 11 (13) 0.28 
Ethnicity   0.84 
 White British 12 (71)  60 (72)  
 South Asian 4 (24) 15 (18)  
 Black 1 (6) 5 (6)  
 Other* 0 (0) 3 (4)  
    
Metformin, n (%) 13 (76) 74 (89) 0.23 
Sulphonylurea, n (%) 5 (29) 28 (38) 1.0 
Gliptin, n (%) 2 (12) 9 (11) 1.0 
Exanatide, n (%) 0 1 (1) 1.0 
Glitazone, n (%) 0 1 (1) 1.0 
Repaglinide, n (%) 0 1 (1) 1.0 
Dapagliflozin, n (%) 0 1 (1) 1.0 
Insulin, n (%) 0 0 - 
ACE inhibitor, n (%) 0 0 - 
Beta blocker, n (%) 2 (12) 2 (2) 0.13 
Calcium channel blocker, n (%) 4 (24) 6 (7) 0.06 
Diuretic, n (%) 1 (6) 4 (5) 1.0 
Statin, n (%) 14 (82) 56 (68) 0.26 
Fibrate, n (%) 0 0 - 
Ezetimibe, n (%) 0 0 -  
Aspirin, n (%) 2 (12) 16 (20) 0.73 
    
CMR     
 LV EDV, ml 140.5±39.1 150.0±32.8 0.30 
 LV EDV index, ml/m2 70.4±17.1 74.5±13.4 0.27 
 Ejection fraction, % 58.0±9.7 61.7±4.9 0.30 
 LV mass, g 102.5±16.3 95.0±21.0 0.34 
 LV mass index, g/m2 51.4±6.5 47.2±8.7 0.01 
 LA volumes, ml 89.0±31.6 88.5±16.8 0.93 
 LA volume index, ml/m2 44.9±15.9 44.2±7.7 0.87 
Feature Tracking     
 GLS -15.2±3.7 -17.7±3.1 0.004 
 SSR -93.8±31.8 -111.2±42 0.04 
 EDSR 64.1±16.6 84.0±33.1 0.02 
 LDSR 87.4±39.9 91.4±41.2 0.89 
Echocardiography     
 E/A ratio 0.75±0.30 0.89±0.30 0.03 
 E/E’ average 7.4±2.4 7.1±2.1 0.96 
 S’ average, cm/s 9.8±2.2 9.5±1.8 0.72 
Electrocardiography     
 Q waves (%) 4 (24) 6 (7) 0.06 
Biomarker findings     
 hs-cTnT, ng/L 7.5±4.1 7.4±5.4 0.42 
 NT-proBNP, ng/L 105.8±132.2 51.9±100.8 0.003 
 hs-CRP, mg/L 3.5±3.5 3.7±5.9 0.57 
 
Table 1. Patient characteristics and investigation findings according to the presence or absence of 
silent MI. *Other ethnicities; 1 Turkish, 1 Polish and 1 Latin American.   
  AUC P value Optimum 
cut-off 
Sensitivity at 
cut-off 
Specificity 
at cut-off 
Q waves 0.582 (0.421-0.742) 0.29 categorical 24% 93% 
Age 0.668 (0.522-0.803) 0.02 >62 76% 63% 
E/A ratio 0.669 (0.526-0.813) 0.02 ≤0.79 71% 59% 
GLS 0.685 (0.542-0.829) 0.01 ≥-18.4% 88% 41% 
NT-proBNP 0.730 (0.604-0.855) <0.001 >29ng/L 88% 57% 
 
Table 2. Area under the curve (AUC) of Q waves and the 4 continuous parameters for detecting silent 
MI. Optimum cut-off, sensitivity and specificity derived from Youden index are also shown   
  
 Silent MI risk 
score 
Sensitivity 95% CI Specificity 95% CI 
0 100.0 - 0.0 - 
≥1 100.0 - 0.0 - 
≥2 100.0 80.5 - 100.0 42.2 31.4 - 53.5 
≥3 82.4 56.6 - 96.2 72.3 61.4 - 81.6 
≥4 41.2 18.4 - 67.1 89.2 80.4 - 94.9 
 
Table 3. Silent MI risk score calculated from age > 62, GLS ≥ -18.4%, EA ratio ≤ 0.79 and NT-
proBNP > 29ng/L. The sensitivity and specificity to detect silent MI for each possible score is shown.  
 
 
  
Figure 1. Examples of silent MI detected by LGE. Horizontal panels are from the same patient and 
white arrows denote the area of MI. A and B show basal and mid inferolateral subendocardial MI. C 
and D show apical and mid septal near transmural infarction. E and F show basal inferior 
subendocardial infarction.  
 
  
Figure 2. Number of patients with silent MI (black) and without silent MI (grey) according to their 
silent MI risk score.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix 1. Receiver operator characteristic curves for age (AUC=0.668, P=0.02), average EA ratio 
(AUC=0.669, P=0.02), NT-proBNP (AUC= 0.730, P<0.001), global longitudinal strain (GLS) 
measured by feature tracking (AUC=0.68, P=0.01), the 4 variable nested model of age, Q waves, EA 
ratio, GLS and NT-proBNP (AUC= 0.85, P<0.0001) and the silent MI risk score using the same 4 
variables (AUC=0.82, P<0.0001). 
 
